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The Williams–Beuren syndrome (WBS) is a contiguous gene syndrome caused by chromosomal rearrange-
ments at chromosome band 7q11.23. Several endocrine phenotypes, in particular impaired glucose tolerance
and silent diabetes, have been described for this clinically complex disorder. TheWBSCR14gene, one of the genes
mapping to the WBS critical region, encodes a member of the basic-helix-loop-helix leucine zipper family of
transcription factors, which dimerizes with the Max-like protein, Mlx. This heterodimeric complex binds and
activates, in a glucose-dependent manner, carbohydrate response element (ChoRE) motifs in the promoter of
lipogenic enzymes. We identified five novel WBSCR14-interacting proteins, four 14-3-3 isotypes and NIF3L1,
which form a single polypeptide complex in mammalian cells. Phosphatase treatment abrogates the associ-
ation between WBSCR14 and 14-3-3, as shown previously for multiple 14-3-3 interactors. WBSCR14 is
exported actively from the nucleus through a CRM1-dependent mechanism. This translocation is contingent
upon the ability to bind 14-3-3. Through this mechanism the 14-3-3 isotypes directly affect the WBSCR14:Mlx
complexes, which activate the transcription of lipogenic genes.
INTRODUCTION
In mammals, the liver is the principal organ responsible for the
conversion of excess dietary carbohydrates to triglycerides, the
predominant storage form of energy. Elevated glucose levels
in the liver lead to either gene transcriptional induction or
post-translational activation of several key enzymes of glyco-
lysis and lipogenesis, including fatty acid synthase, acetylCoA
carboxylase and L-type pyruvate kinase (LPK) (1–3). The
carbohydrate responsive element binding protein (ChREBP)
transcription factor, the rat ortholog of Williams–Beuren syn-
drome critical region gene 14 [hereafter named WBSCR14
following recommendation of the HUGO Gene Nomenclature
Committee (4)] is expressed under high-glucose diet and inhib-
ited under high-fat diet in primary cultured hepatocytes. Its over-
expression in these cells results in increased transcription of the
LPK gene through direct binding of the carbohydrate response
element (ChoRE) of the LPK promoter (5–9). The WBSCR14
gene encodes a member of the basic-helix-loop-helix leucine
zipper (bHLHZip) family of transcription factors (10), which
dimerizes with the Max-like protein, Mlx, to bind E-box
motifs in the promoter region of target genes (7,11). High-
glucose level activates the nuclear translocation and the DNA-
binding activity of rat WBSCR14, through Ser196 and Thr666
dephosphorylation by xylulose 5-phosphate-activated protein
phosphatase 2A in primary hepatocytes (12). Conversely, gluca-
gon and fatty acids increase the level of AMP and cAMP in
hepatocytes activating AMPK and/or PKA, which results in
the phosphorylation of WBSCR14 at residue Ser568 and inhi-
bition of its DNA-binding activity (5,6,9,12). Recent obser-
vations demonstrated that rat WBSCR14 plays also an
essential role in the regulation of other lipogenic enzymes,
besides LPK, involved in glucose and lipid metabolism (12–14).
Williams–Beuren syndrome patients (WBS, OMIM#194050)
are hemizygous for the WBSCR14 gene (8,15). WBS is a
neurodevelopmental disorder characterized by numerous
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clinical aspects including mental retardation with unique cog-
nitive and personality profile (16,17). The cognitive hallmark
of WBS individuals is dissociation between language (relative
strength) and spatial cognition (profound impairment). The
WBS incidence is estimated at 1/20 000 and sporadic de
novo inheritance is usual. The molecular basis of the syndrome
is a heterozygous 1.5 Mb microdeletion or rarely an inver-
sion at chromosome band 7q11.23. While our understanding
of the etiology of WBS has improved greatly, the molecular
basis of all except the cardiovascular phenotype remains
unknown (18–22). Approximately 75% of the WBS patients
show impaired glucose tolerance (IGT) or silent diabetes
(17). The elevated glucose levels of these patients suggest
that glucose uptake plays a role in the occurrence of these phe-
notypes. We surmise that they could be related to WBSCR14
hemizygosity and to the ability of this transcription factor to
control the expression of lipogenic enzymes.
We performed a yeast two-hybrid selection to identify
proteins that regulate the function of WBSCR14. In this
report, we describe five new Wbscr14-interactors. These pro-
teins participate in the regulation of WBSCR14-dependent
transcription, through control of the subcellular localization
of the ChoRE-binding protein.
RESULTS
Two-hybrid selection
To identify new proteins that interact with WBSCR14, and
potentially regulate its nuclear translocation, we performed a
yeast two-hybrid selection using two human cDNA libraries
(from HeLa cells and human fetal brain). A fusion between
LexA and mouse Wbscr14-z residues 81–297 was used as
bait. This construct encompasses the protein amino-terminal
domain of repression (PADRE, Fig. 1A), which was shown
to repress transcription when fused to the GAL4 DNA
binding domain (7). Repression was accomplished through
retention of the GAL4 moiety outside of the nucleus (23).
This selection allowed us to identify five potential novel
Wbscr14-interactors.
Wbscr14 interacts with 14-3-3
Four of these interactors were cloned from both screened
libraries. They correspond to different 14-3-3 isotypes, specifi-
cally 14-3-3 b, g, z and u. Because large proteins with mul-
tiple 14-3-3 docking sites have been described (24), we
tested if more than one 14-3-3-binding moiety existed on the
Wbscr14 protein using the interaction–mating technology
(25). A panel of overlapping Wbscr14 peptides expressed as
fusion proteins with the LexA–DNA binding domain (bait)
was tested for interaction with 14-3-3 b, z and u and Mlx-a
fused to the B42-acidic moiety (prey). Consistent with pre-
vious results, Wbscr14, bHLHZip (584–765), WMC (737–
864) and PADRE (1–146 and 81–297) domains interact
with Mlx (7) and 14-3-3 b, z and u isotypes (see above),
respectively. In addition, we found that 14-3-3 b and z also
interact with the Wbscr14 584–765 peptide, suggesting that
two independent 14-3-3-binding moieties are present on the
Wbscr14 protein (Fig. 1A and B).
Figure 1. Phosphorylated Wbscr14 interacts with 14-3-3. (A) Schematic
representation of the Wbscr14-z domains (defined in 7). The PADRE was
used as bait in the two-hybrid selection. MADRE: middle activation domain
as in RelB; bHLHZip: basic helix-loop-helix leucine zipper domain; WMC:
WBSCR14-Mlx C-tail homologous domain. The white box within the
PADRE domain represents the NES domain. (B) Interaction–mating assays
between EGY42 bait strains carrying LexA fusions to overlapping Wbscr14-
z peptides and EGY48 derivatives that contain B42 fusions to human Mlx-b
and 14-3-3 b, z and u isotypes. The ‘þ ’ signs denote interaction as measured
by lacZ expression and LEU2 expression on galactose/raffinose media,
whereas empty cells indicate no interaction. (C) Wbscr14 interacts with
endogenous 14-3-3. COS-7 cells were transfected with plasmids expressing
HA–Wbscr14-z. Lysates were immunoprecipitated with anti-HA mAb (lane
2), anti-Wbscr14 (3), its preimmune counterpart (4) or an unrelated antisera
(5) as specified above. Immunoprecipitated complexes were revealed by
immunoblotting with an anti-14-3-3 (top panel) or an anti-HA (bottom
panel) antibody. The anti-14-3-3 antibody used recognizes all seven 14-3-3
isotypes. Abbreviations: WB, western blotting with specified antibody;
IP, immunoprecipitation with specified antibody. (D) Wbscr14 residues
117–133 are essential for 14-3-3-binding. HA–Wbscr14-z (left lane) and
HA–Wbscr14-z D117–133 (right lane) were transfected transiently in
COS-7 cells. Lysates were immunoprecipitated with an anti-HA mAb and
revealed by immunoblotting with an anti-14-3-3 (top panel) or an anti-HA
(bottom panel) antibody. (E) Dephosphorylation of Wbscr14 disrupts its
interaction with 14-3-3. The anti-Wbscr14 immunoprecipitate from (C) was
dephosphorylated with alkaline phosphatase (right lane) or mock treated
(left lane) and probed for binding to in vitro labeled and transcribed 14-3-3
u (top panel). Stripping and reprobing the membrane with an anti-HA antibody
showed that similar amounts of Wbscr14 protein were used in each lanes
(bottom panel). Abbreviations: FW, far western blotting with specified
interactor.
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To determine if Wbscr14 binds to the COS-7 endogenous
14-3-3 isotypes, total cell lysates of HA–Wbscr14-z trans-
fected cells were immunoprecipitated with immune and pre-
immune sera raised against Wbscr14, with immune sera
raised against an unrelated protein or with an anti-HA mono-
clonal antibody. The precipitated proteins were separated by
gel electrophoresis and subjected to immunoblot analysis
using antibodies reactive against 14-3-3 mammalian isotypes.
The 14-3-3 proteins were found in the anti-HA and anti-
Wbscr14 immunoprecipitates, but not in the controls (Fig. 1C,
compare lanes 2 and 3 with 4 and 5). Similarly, we could
immunoprecipitate complexes containing endogenous 14-3-3
and transfected HA–Wbscr14-z proteins from 293T cells
(data not shown). This interaction is not specific to certain iso-
types, as HA–Wbscr14 protein co-precipitates with 14-3-3 b,
g/h, 1, z and u isotypes (data not shown). Interaction with
the s (stratifin) isotype could not be tested, as we were
unable to detect this form in COS-7 cells (data not shown).
To better define the Wbscr14 N-terminal 14-3-3-binding
moiety, we created three deletion mutants: HA–Wbscr14-z
D86–95, D103–114 and D117–133. These deletions span the
Wbscr14 PADRE domain essential for the 14-3-3-
interaction. Deletion of residues 117–133 completely abrogates
interaction with 14-3-3, whereas the other mutants retain their
affinity (Fig. 1D and data not shown). This result also indicates
that the second 14-3-3-binding site of Wbscr14 (see above)
might correspond to a low affinity site not essential for the for-
mation of the complex, but only for its stability (24).
Because 14-3-3 proteins are known to often bind proteins
containing phosphothreonine or phosphoserine motifs (24),
we questioned whether the phosphorylation status of
Wbscr14 would influence 14-3-3-binding. Membrane-
fixed mock and alkaline phosphatase treated HA–Wbscr14-z
proteins were tested for binding to in vitro translated and
labeled 14-3-3 u. The phosphatase treatment abrogates
Wbscr14:14-3-3 u association suggesting that phosphorylation
of the bHLHZip transcription factor is required for interaction
(Fig. 1E). As no sequence resembling a 14-3-3 binding con-
sensus maps to the region between residues 117 and 133 of
Wbscr14-z, we surmise that the phosphorylation-dependent
interaction observed occurs indirectly through a protein
present in rabbit reticulocyte lysates that bridges 14-3-3 and
Wbscr14. Alternatively, the phosphorylation status of
Wbscr14 could influence the folding, hence abolishing the
interaction with 14-3-3.
Recently, the phosphorylation status of residues S196,
S568, S626 and T666 was shown to play a crucial role in
the nuclear localization and DNA-binding activity of the
Wbscr14 rat ortholog in primary rat hepatocytes (6). We
tested whether mutants mimicking the unphosphorylated
state of these and the S140 residues were still able to interact
with the 14-3-3 protein. None of the single mutants, Wbscr14-
z S140A, S196A, S568A, S626A and T666A, showed an
impaired affinity for 14-3-3 (Supplementary Material,
Fig. S1A). We next tested whether phosphorylation of these
residues exerts a cooperative effect on the interaction. For
this, we created a quadruple mutant (S196A/S568A/S626A/
T666A) and investigated its ability to interact with 14-3-3.
Again, this mutant shows no alteration in its affinity for
14-3-3 (Supplementary Material, Fig. S1A). These results
confirm that the phosphorylation status of these residues are
not involved directly in the ability of Wbscr14-z to interact
with 14-3-3.
14-3-3 u expression specifically represses the
transcriptional activity of Wbscr14-z
As heterodimers formed between Wbscr14 and Mlx activate
the transcription of an E-box driven Luciferase construct and
the LPK gene promoter (G. Merla and A. Reymond, unpub-
lished data) (14), we inquired whether 14-3-3 proteins could
act as regulators of Wbscr14-z transcriptional activity.
Expression of increasing amounts of 14-3-3 u leads to the
repression of Wbscr14-z:Mlx-mediated transcription in a
dose-dependent manner, indicating that 14-3-3 u controls the
Wbscr14 activity (Fig. 2A and B). To confirm the specificity
of this effect, we repeated the experiment using Wbscr14-z
D117–133, a Wbscr14 mutant heterodimerizing with Mlx
and activating transcription of E-box-driven reporters, yet
unable to bind 14-3-3 (see above and Fig. 1D). This mutant
shows a lower relative activity when compared with its
wild-type counterpart (Fig. 2A), probably reflecting a dimin-
ution of the stability of the protein as seen by western blot
(data not shown). The results show no influence of 14-3-3
on the transcriptional activation mediated by Wbscr14-z
D117–133:Mlx complex demonstrating that 14-3-3 specifi-
cally regulates Wbscr14 transcription (Fig. 2A).
Wbscr14, NIF3L1 and 14-3-3 form a complex
The two-hybrid screening of the human fetal brain library
revealed a fifth potential Wbscr14-interactor besides 14-3-3
isotypes. We isolated two identical clones corresponding to
the entire open reading frame of an as yet unidentified
Ngg1-interacting factor 3-like 1 (NIF3L1) isoform, we
named NIF3L1-g (AY251944). NIF3L1-g shares with the
original NIF3L1 seven-exon transcript [which we named
isoform a; AF283538; (26)] the first two coding exons, but
differs by skipping exons 5 and 6 and using cryptic donor
and acceptor sites in exon 4 and 7, respectively (Fig. 3A).
NIF3L1-g is predicted to encode a 252 residues putative
protein. We characterized another alternatively spliced
isoform, isoform b, which skips exon 5 and encodes a 285
residues putative protein (AY251943, Fig. 3A). A fourth
splice variant (NIF3L1-d; AK023378) with a different
50-UTR and first ATG codon was also reported (Fig. 3A) (27).
To confirm the interactions between Wbscr14 and NIF3L1
in mammalian cells, co-immunoprecipitation experiments
were carried out in transiently transfected COS-7 (Fig. 3B)
and 293T (data not shown) cells with plasmids expressing
Myc–EGFP–NIF3L1-a and HA–Wbscr14-z fusion proteins.
Lysates were immunoprecipitated with anti-HA antibodies or
anti-Wbscr14 antisera (7) and probed with anti-GFP specific
antibodies. Tagged NIF3L1-a was precipitated exclusively
in the presence of HA–Wbscr14-z, confirming that NIF3L1
and Wbscr14 interact in mammalian cells (Fig. 3B and C).
These results, together with the two-hybrid screen results,
indicate that the Wbscr14-interacting domain of NIF3L1 is
encoded by the first three exons of the gene.
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To determine if Wbscr14, 14-3-3 and NIF3L1 are possibly
present in a single protein complex, we tried to immunopreci-
pitate 14-3-3 proteins from Myc–EGFP–NIF3L1-a trans-
fected COS-7 lysates with anti-GFP antibodies. 14-3-3 was
immunoprecipitated in the presence of EGFP–NIF3L1, but
not in the presence of EGFP alone showing that 14-3-3 inter-
acts with NIF3L1 (Fig. 3C and D). Taken together, these
results suggest that WBSCR14:14-3-3:NIF3L1 form a
complex in mammalian cells. As expression of 14-3-3 u
leads to the repression of Wbscr14-z:Mlx-mediated transcrip-
tion in a dose-dependent manner (see above), we investigated
if a similar effect will be obtained upon expression of NIF3L1-
a. On the contrary, expression of increasing amounts of
NIF3L1 slightly increases the Wbscr14-mediated transcrip-
tional activity (Fig. 2A).
Subcellular localization of Wbscr14, 14-3-3 and NIF3L1
As previously reported, immunofluorescence microscopy
shows that Wbscr14, 14-3-3 and NIF3L1-a localize in the
cytoplasm (5,26,28,29). Similarly, Myc–EGFP–NIF3L1-b
and Myc–EGFP–NIF3L1-a–L244X show staining in the
cytoplasm of COS-7 cells (Supplementary Material, Fig. S2).
HA–Wbscr14-z, Myc–EGFP–NIF3L1-a and endogenous
14-3-3 co-localize in the cytoplasm of (co-)transfected 293T,
COS-7, HeLa and U2OS cells, providing further evidence
that they associate in vivo (Supplementary Material, Fig. S3
and data not shown). Mutations of residues S196, S568,
S626 and T666 individually or together did not alter the
cytoplasmic localization of HA–Wbscr14-z (Supplementary
Material, Fig. S1B and data not shown).
As 14-3-3 proteins promote the cytoplasmic localization
of many binding partners by interfering with the function of
nuclear localization signals (NLS) or nuclear export seq-
uences (NES) (30), and because high glucose and fatty
acids levels were recently shown to regulate the nuclear trans-
location of the WBSCR14 rat ortholog in primary hepatocytes
(6), we investigated if the cytoplasmic localization of
Wbscr14 and NIF3L1 in COS-7 cells was dependent on
active nuclear export. Co-transfected COS-7 cells were
treated with the CRM1-dependent nuclear export inhibitor
Leptomycin B (LMB) (31). The results, as well as examples
of subcellular localization, are presented in Figure 4.
Figure 2. Overexpression of 14-3-3 u specifically represses transcriptional
activity of Wbscr14-z. (A) Relative luciferase units (RLU) of 293T cells trans-
fected with the specified expression plasmids and the pTK81 4  [E-box]–
luciferase reporter. The relative activity of Wbscr14-z:Mlx (purple) and
Wbscr14-z D117–133:Mlx (burgundy) complexes is competed with increasing
amounts of 14-3-3 u, whereas the relative activity of Wbscr14-z:Mlx upon pre-
sence of NIF3L1-a is shown in yellow. For comparison, the corresponding
control activity (orange) is indicated. ‘þ’ and ‘3þ’ signs denote transfections
with 400 and 1200 ng of plasmid, respectively. Relative amounts of expressed
fusion proteins were assayed by western blotting (data not shown). (B) RLU of
293T cells transfected with the specified expression plasmids and the
PK(-183)Luc reporter [color code and abbreviations as in (A)].
Figure 3. (A) Schematic representation of the human NIF3L1 gene (top) and
alternatively spliced transcripts (below). Exons are depicted as filled (coding)
and unfilled boxes (50-and 30-UTR). The sizes in bp of exons and introns are
indicated above, whereas the size in amino acid residues of the putatively
encoded proteins are specified on the right. Exons and introns are not
to scale. (B–D) Wbscr14, NIF3L1 and 14-3-3 form a complex. COS-7 cells
were co-transfected with the specified expression plasmids. Lysates were
immunoprecipitated with an anti-HA (IP:HA), an anti-Wbscr14 (IP:WB14)
or an anti-GFP antibody (IP:EGFP) and revealed by immunoblotting with
an anti-GFP (WB:EGFP) or an anti-14-3-3 antibody (WB:14-3-3).
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A primarily cytoplasmic localization of HA–Wbscr14-z and
Myc–EGFP–NIF3L1-a is shown by 89+ 6% and 77+ 4%
of COS-7, respectively (Fig. 4A–D and I). Upon treatment
with LMB, Wbscr14 is retained in the nucleus of 83+ 9%
of the analyzed cells. In contrast, the subcellular localization
of NIF3L1 remains cytoplasmic (74+ 9% of cells with a
predominantly cytoplasmic signal; Fig. 4E, F, G, H and I).
Similar localizations were observed with single transfections
(data not shown). These results show that Wbscr14
shuttles between the cytoplasm and the nucleus, from which
it is actively exported, whereas NIF3L1 is uniquely
cytoplasmic.
Mapping of the Wbscr14 NES activity
To map the Wbscr14 NES activity, we transfected HA-tagged
Wbscr14-z overlapping peptides (Fig. 5A) and analyzed their
subcellular distribution in the presence and absence of LMB.
The two N-terminal peptides 1–146 and 81–298/PADRE
show a cytoplasmic and a nuclear localization in the presence
and absence of LMB, respectively, whereas the four other
investigated peptides show a predominantly nuclear (272–
417; 374–643/MADRE and 584–765/bHLHZip) or predomi-
nantly cytoplasmic (737–864/WMC) localization under both
conditions (Fig. 5B). These results suggest that either
Figure 4. Wbscr14 is exported actively from the nucleus. (A–H) Examples of fluorescence microscopy of fixed DAPI-counterstained COS-7 cells transiently
co-transfected with HA–Wbscr14-z and Myc–EGFP–NIF3L1-a mock treated (A–D) or treated with LMB (E–H). EGFP fluorescence: B, D, F and H; staining
with anti-HA mAb and AlexaFluor 568-coupled goat anti-mouse antibody: A, D, E and H; DAPI: C, D, G and H. (I) Quantification of the subcellular localization
of HA–Wbscr14-z (left) and Myc–EGFP–NIF3L1-a (right) in LMB and mock treated COS-7 cells upon co-transfection of equal amounts of both plasmids.
Results are indicated as the percentage of cells expressing fluorescence in the cytoplasm (purple, e.g. A, B and F), the nucleus (pale yellow, e.g. E) and
both cellular compartments (burgundy). Please note that upon inhibition of the CRM1 nuclear export pathway Wbscr14 is retained in the nucleus, whereas
NIF3L1 remains cytoplasmic.
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the Wbscr14 NES maps between residues 81 and 146 or these
residues are forming an interacting-moiety, which allows
Wbscr14 to interact with an NES-containing protein. Further-
more, they indicate that the three peptides 272–417, 374–
643/MADRE and 584–765/bHLHZip, either contain an NLS
or interact with an NLS-containing protein. Finally, it indicates
that the 737–864/WMC peptide holds a section allowing cyto-
plasmic retention. Consistently, a similar C-terminus portion of
MondoA, a WBSCR14 paralog, recently was shown to include
a cytoplasmic localization domain (7,23,32). Between residues
81 and 146, the sequence 86LTHLFECLSL95 conforms to the
NES signature (L-x(2,3)-[LIVFM]-x(2,3)-L-x-[LI]) (33). To
confirm that this stretch of residues was participating in the
active nuclear export of Wbscr14-z, we engineered a double
mutant by changing two of the characteristic NES signature
residues. The Myc–EGFP–Wbscr14-z, L86A/L93A mutant
protein, as its wild-type counterpart, is distributed diffusely in
the cytoplasm and nucleus in the absence and presence of
LMB, respectively, in the same proportion (Fig. 5B). This
indicates that the Wbscr14 NES-like sequence is not necessary
to actively export the protein from the nucleus. This mutant
retains its ability to bind 14-3-3 corroborating the previous
mapping of the 14-3-3-binding domain of Wbscr14 to a more
distal region of the protein (Fig. 1B and data not shown).
DISCUSSION
The human gene that encodes the WBSCR14 protein maps
to 7q11.23, a region commonly deleted in WBS patients.
Homozygous deletions of contiguous gene syndrome regions
are usually lethal, and in a heterozygote only the dosage-
sensitive genes will affect the phenotype. It is thus a challenge
to determine which of the WBS hemizygote genes causes
the various phenotypes of the syndrome (18,19,34,35). ELN
haploinsufficiency has been linked to supravalvular aortic
and other stenoses (21,36,37), whereas a mouse model
suggests that CYLN2 hemizygosity might contribute to the
WBS cognitive profile (38). Furthermore, the study of WBS
patients with atypical deletion suggests that GTF2IRD1,
GTF2I and CYLN2 genes might contribute to the visual
spatial processing deficits harbored by WBS patients
(39,40). However, the gene(s) responsible for the IGT and
Figure 5. The nuclear export activity of Wbscr14 maps to the PADRE domain. (A) Representative examples of subcellular localization of the HA-tagged
Wbscr14-z peptides schematically depicted on the left in the absence (left column) and presence (right column) of LMB. (B) Representative examples of sub-
cellular localization of the Myc–EGFP–Wbscr14-z, WT and L86A/L93A mutant schematically depicted on the left in the absence (left column) and presence
(right column) of LMB.
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silent diabetes reported in the majority of the WBS patients
remains to be determined.
Triglycerides can be synthesized from fatty acids obtained
through the diet or produced through de novo synthesis from
the metabolic intermediate acetyl-CoA. This lipogenesis
pathway is regulated by controlling the activity of key
enzymes in response to dietary status. This response is
thought to be adaptive and occurs in large part through tran-
scriptional regulation of genes encoding lipogenic enzymes
(3,41–43). Consistently, in the liver, in response to excess
carbohydrate in the diet, the labile WBSCR14, also known
as ChREBP binds to the stable Mlx protein to bind E-box
elements and activates the transcription of lipogenic genes
(5–9,11,14). Inhibition of WBSCR14 activation is therefore
expected to attenuate excess fat accumulation resulting from
a high-carbohydrate diet. The nuclear translocation of
WBSCR14 is controlled by the dephosphorylation of key resi-
dues by xylulose 5-phosphate-activated protein phosphatase
2A (5,6,12). To identify proteins, which might participate in
the nuclear export/import of WBSCR14, we searched for pep-
tides interacting with the PADRE region, previously shown to
repress transcription when fused to a DNA-binding domain
(7). In this report, we describe the isolation of five such pro-
teins through two-hybrid selection, four 14-3-3 isotypes and
NIF3L1.
The 14-3-3 proteins induce the cytoplasmic translocation
and/or retention of its binding partners by masking intrinsic
NLSs (e.g. CDC25C) or unmasking intrinsic NESs (e.g.
HDAC4 and HDAC5) (44–48). This translocation might
be facilitated further through a NES present on the
C-termini of 14-3-3 isotypes (49). We showed here that
WBSCR14 is exported actively from the nucleus through a
CRM1-dependent mechanism in COS-7 cells. This activity
was mapped between residues 81 and 146 and is not depen-
dent on the integrity of the WBSCR14 NES-like sequence
(residues 86–95). Consistently, the dissection of the function
of the different regions of MondoA, a WBSCR14 paralog,
using singled-out domains revealed that the region responsible
for its cytoplasmic localization resides on its N-terminus (32),
a region previously shown to be conserved among WBSCR14,
MondoA and their Caenorhabditis elegans and Drosophila
melanogaster orthologs (7). The WBSCR14 export, how-
ever, is contingent upon the ability to bind 14-3-3, as
expression of increasing amounts of 14-3-3 represses the
transcriptional activity of WBSCR14:Mlx complexes in a
dose-dependent manner, but not that of heterodimers contain-
ing a WBSCR14, which lack the 14-3-3-interaction site
(Wbscr14-z D117–133, this work). These results suggest
that either WBSCR14 uses the 14-3-3 NES to be exported
actively from the nucleus or 14-3-3 creates a link between
WBSCR14 and an yet unidentified protein containing an
active NES. In many cases, the binding to 14-3-3 and thus
the cytoplasmic translocation of the interacting proteins is
dependent on their phosphorylation status (50). Consistently,
our study shows that the phosphorylation of Wbscr14-z is
important for the 14-3-3-interaction in COS-7 cells. We
were unable to identify a specific residue involved in this
interaction. Either the engineered alanine mutants at residues
196, 568, 626 and 666 failed to mimic correctly the
WBSCR14 dephosphorylated state or the phosphorylation
status of an unknown protein is key to bridge 14-3-3 and
WBSCR14. Interestingly, the nuclear import/export of
WBSCR14 seems to be controlled differently in distinct
cells as WBSCR14 alanine mutants translocate to the
nucleus in primary rat hepatocytes (6), but fail to do so in
COS-7 and 293T cells (Supplementary Material, Fig. S1B).
The shuttling of WBSCR14 between the cytoplasm and the
nucleus, as revealed by our LMB assays, is probably under the
control of fast export and import processes, to avoid untimed
activation of target genes. The 14-3-3 proteins might not only
regulate WBSCR14 transcription activity through export
control, but also slow down WBSCR14 nuclear entry by
masking its NLS or by preventing its dephosphorylation, as
shown for the BAD proapoptotic protein (51). However, our
observation that the WBSCR14D117–133 mutant, which
lacks the 14-3-3-interaction moiety, is localized predomi-
nantly in the cytoplasm of 293T, COS-7, HeLa and U2OS
cells does not support this hypothesis.
In our screen for novel WBSCR14-interactors we also
identified NIF3L1. NIF3L1 is the ortholog of the yeast
Ngg1-interacting factor 3 (NIF3) (26). The yeast yNIF3p
was shown to interact with yNGG1p (52), now designated
yADA3p, a subunit of histone acetyltransferase (HAT) com-
plexes (53,54). Reciprocally the human homolog of
yADA3p, ADA3, was identified in the PCAF and the
hGCN5-containing HAT complexes (55). Moreover, loss of
yADA3 or of its partner yADA2 affects transcription of a
large number of genes and inhibits the rapid global increase
in transcription that occurs in response to glucose, as yeast
cells resume rapid growth and accelerate progress through
the cell cycle (56). The mouse Nif3l1 protein was shown
recently to interact with Trip15/CSN2, a transcriptional co-
repressor/component of the COP9 signalosome thereby
executing a crucial role in retinoic acid-primed neural differ-
entiation of P19 embryonic carcinoma cells (28). Interestingly,
the Wbscr14-interacting domain maps to the first 243 residues,
whereas the Trip15/CSN2-binding moiety was shown to
map to the COOH-terminus (residues 243–376) (this work
and 28). These observations suggest that NIF3L1, like its
yeast counterpart, functions as a corepressor/coactivator of
key transcription regulators complexes. Through
immunoprecipitation and subcellular localization, we show
that NIF3L1, 14-3-3 and Wbscr14 are interacting in the cyto-
plasm of all cell lines tested. Yet in contrast to Wbscr14 and
14-3-3, NIF3L1 does not appear to shuttle between the cyto-
plasm and the nucleus. Thus, we hypothesized that NIF3L1
might modulate the activity of Wbscr14-containing complexes
by retaining them in the cytoplasm. Overexpression of
NIF3L1 partially increases the Wbscr14-mediated transcrip-
tional activity (Fig. 2A). This observation is consistent with
the bridge model, where 14-3-3 is necessary to link NIF3L1
and Wbscr14 and with the ability of NIF3L1 to sequester
14-3-3 in the cytoplasm.
In conclusion, the results presented here indicate that 14-3-3
isotypes (and NIF3L1) regulate the transcriptional activity of
Wbscr14 by modulating its subcellular localization. Hence,
14-3-3 proteins appear to be important regulators of the
Mlx-driven transcription factor (this work and 32). The regu-
lation of glucose metabolism by Wbscr14 supports the hypoth-
esis that the diabetic phenotype observed in WBS patients
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could be related to WBSCR14 hemizygosity (5,6,9,14,57).
The hemizygosity of this transcription factor could reduce
its ability to respond to high-glucose diet through activation
of the expression of enzymes involved in de novo triglycerides
synthesis using glucose precursors. Further experiments will
be needed to clarify unambiguously this item.
MATERIALS AND METHODS
Yeast two-hybrid selection
The LexA based yeast two-hybrid selection was performed as
described (58). Interaction-mating was used to confirm inter-
action after isolation of two-hybrid positive clones (25). As
judged by western gel analysis of bait fusions with anti-
LexA antibody, the engineered Wbscr14 mutants were
expressed to the same level as their wild-type Wbscr14
counterpart (data not shown).
Genes, mutants and plasmids
Bait plasmids expressing Wbscr14 peptides fused to the first
202 residues of LexA under the control of the constitutive
ADH promoter were created. Wbscr14-z cDNA fragments
were PCR amplified and cloned directionally in pAR405, a
pJG4-5 vector modified to include a new multiple cloning
site and no restriction sites after the ADH terminator
(58,59). Screening of the human dbEST database with
NIF3L1-a allowed to identify ESTs showing skipping of
exon 5. The structure of this newly identified isoform,
named NIF3L1-b, was confirmed by RT–PCR. Human full-
length cDNAs for NIF3L1-a and 14-3-3 u were RT–PCR
amplified from 293T cell RNA. PCR products were cloned
into pCDNA3 vectors modified to include either a Myc-
tagged EGFP or an HA tag (59). The pCDNA3 HA–
Wbscr14-z and pTK81 4  [E-box]–luciferase reporter
vectors were described previously (7). Deletions to engineer
NIF3L1 isoforms from the NIF3L1-a template and missense
mutations were generated with the QuickChange site-directed
mutagenesis kit (Stratagene) following the manufacturer’s
protocol. All constructs and mutants were verified by DNA
sequencing.
Cell culture and transfection
293T, COS-7, HeLa, U2OS cells (ATCC) were maintained in
Dulbecco’s modified Eagle’s medium (Invitrogen) sup-
plemented with 10% fetal bovine serum (FBS). COS-7, 293T,
HeLa and U2OS cells were transfected with Lipofectamine
Plus (Invitrogen) or Fugene6 (Roche) according to the manu-
facturers’ instructions.
Immunoprecipitation and western blot
Co-immunoprecipitation experiments were performed as
described previously (11,60). Briefly, 48 h post-transfection
cells were washed in 1  phosphate-buffered saline (PBS),
and whole-cell lysates were suspended in lysis buffer
[1  PBS, 0.25% NP-40, 1 mM phenylmethylsulfonyl fluoride
with Complete Protease Inhibitor Cocktail (Roche)] and
incubated on ice for 30 min. Equal amounts of proteins were
mixed with the appropriate antibodies and rocked at 48C over-
night. After addition of Protein A–Sepharose or Protein
G–Sepharose and incubation for one more hour at 48C, proteins
were immunoprecipitated and washed five times with lysis
buffer. Complexes were analyzed by western blotting using
anti-GFP polyclonal antibodies (Santa Cruz Biotechnology),
anti-HA (12CA5, Roche and BaBCO, Berkeley Antibody
Company), or anti-14-3-3 antibodies (H-8 SC-1657, recogniz-
ing all 14-3-3 isotypes; C-20 SC-628, C-16 SC-731, T-16 SC-
1020, C-16 SC-1019, C-17 SC-732 and C-18 SC-7683 recog-
nizing 14-3-3 isotypes b, g, 1, z, u and s, respectively, all
from Santa Cruz Biotechnology). Horseradish peroxidase
(HRP)-conjugated anti-goat (Santa Cruz Biotechnology),
anti-mouse and anti-rabbit antibodies (Amersham-Pharmacia)
and the ECL chemiluminescence system (Amersham-
Pharmacia) were utilized for detection. For the phosphatase
experiment, HA–Wbscr14 co-immunoprecipitated from tran-
siently transfected COS-7 cells with anti-Wbscr14 sera and
bound to Protein A–Sepharose beads, was washed four
times with ice-cold lysis buffer and twice with phosphatase
buffer [50 mM Tris–HCl (pH 8.5), 0.1 mM EDTA], resus-
pended in 50 ml of phosphatase buffer and incubated with or
without alkaline phosphatase (20 U/ml; Roche) for 2 h at
378C. Beads were retrieved by centrifugation and bound pro-
teins eluted by boiling in SDS–PAGE buffer. Separated pro-
teins were transferred to polyvinylidene difluoride (PVDF,
Millipore) membranes, soaked in far western solution
(1  PBS, 5% non-fat dry milk, 0.1% Tween) for 1 h at
room temperature and incubated overnight at 48C in far
western solution supplemented with 50 ml of rabbit reticulo-
cyte lysate-expressed [35S]Met-labeled 14-3-3 u produced
with the TNT coupled transcription/translation system
(Promega). The blot was then washed six times with far
western solution without non-fat dry milk, dried and autora-
diographed with a Molecular Imager (BioRad).
Subcellular localization
Transfected cells were fixed in 1  PBS containing 4%
formaldehyde for 20 min at room temperature, washed
with 1  PBS, permeabilized with 0.1% Triton X-100 and
blocked 1 h with PBS/1% bovine serum albumin (BSA). The
anti-HA antibody and the secondary anti-mouse AlexaFluor
568 (Molecular Probes) were used at 1:1000 and 1:500
dilutions, respectively. Cells were incubated for 1 h with the
primary antibody at room temperature. After extensive
washing with PBS, cells were incubated for 1 h at room temp-
erature with secondary antibody. Nuclei were stained with
DAPI (1 mg/ml). To quantify subcellular localization, indepen-
dent transfections were carried out at least three times, and not
less than 100 cells were counted for each transfection. In
co-transfections, only cells expressing both proteins were
scored. For shuttling experiments, cells were treated with
10 ng/ml LMB for 12 h (61).
Transcription assays
An amount of 2.0  105 293T cells were co-transfected with
400 ng of pCDNA3 HA–Wbscr14-z wild-type or mutant,
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400 ng of pCDNA3 HA–Mlx, 950 ng of pTK81 4  [E-box]–
luciferase reporter (7) or PK(-183)Luc (62) and 400 or
1200 ng of pCDNA3 HA–14-3-3 u. Fifty nanograms of
pRL-SV40 (Promega) and Salmon sperm were added to
measure transfection efficiency and to balance the quantity
of final DNA, respectively. After 36 h post-transfection, cells
were harvested and luciferase activity was measured by dual
luciferase reporter assay system following the manufacturer
protocol (Promega). The results are expressed as the relative
luciferase activity of the appropriate control. The experiments
were carried out three times in triplicate.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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